

Special Issue

Transcriptomics and Non-coding RNAs in Heart Failure

Message from the Guest Editor

Heart failure is a shared chronic phase of cardiac functional impairment secondary to many etiologies and considered a serious global health challenge affecting at least 26 million people worldwide. There is a need to develop new strategies for the management of this syndrome. In this sense, alterations in the gene expression of different pathways that can lead to heart failure are being studied. Gene expression requires precise regulation through selective and bidirectional transport between the nucleus and the cytoplasm, including membrane proteins, enzymes, ribosomal subunits, and different types of RNAs. Noncoding RNAs are emerging as potent and multifunctional regulators in all biological processes, and step by step, studies are unveiling associations between aberrant noncoding RNA expression and human diseases. Better known are miRNAs, emerging evidence has demonstrated that abnormal expression is associated with the pathological processes of cardiovascular diseases, although their functional roles have not been completely understood. This can be contrasted to the lack of information around the expression of other sRNA as snoRNAs or scaRNAs, especially at the cardiac level.

Guest Editor

Dr. Estefanía Tarazón

1. Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe), Valencia, Spain
2. Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Madrid, Spain

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/102291

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).